NCT00079976View on ClinicalTrials.gov

Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

PHASE3CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Gram-Positive Bacterial InfectionsStaphylococcus InfectionsVancomycin ResistanceMethicillin Resistance
Interventions
DRUG

Tigecycline

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00079976 - Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) | Biotech Hunter | Biotech Hunter